52 results about "DNA Aptamers" patented technology

The invention relates to the technical field of biological medicines, in particular to a preparation method of an inhibitor targeting a MAX-PD-L1 promoter specific binding motif and a double-target inhibitor, through ChIP-seq and site-directed mutagenesis experiments, a core binding motif of MAX and a PD-L1 promoter, such as 5 '-CAC [GA] TG-3', is defined, it is ensured that the inhibitor only targets a key site of MAX-PD-L1 interaction, and the activity of the MAX-PD-L1 promoter specific binding motif is improved. The off-target effect is avoided, and a high-specificity target spot is provided for subsequent inhibitor design. The cell permeability of the DNA aptamer screened based on the specific binding motif is improved after cholesterol modification, and the affinity of the DNA aptamer is obviously higher than that of a traditional antibody. A small molecule compound virtually screened through a molecular docking model is optimized through hydrogen bond and hydrophobic interaction, and then the binding affinity with MAX is improved. After treatment with the inhibitor, the combination inhibition rate of MAX and the PD-L1 promoter is high, the transcriptional activity of PD-L1 is obviously reduced, the killing rate of T cells to tumor cells is also improved, and immune escape is effectively blocked.

The application belongs to the field of chemical biology, and relates to a Fusobacterium nucleatum single-stranded DNA aptamer and a screening method and kit. The nucleotide sequence of the aptamer is as follows: 5'-TGACTGACGACGACTCCGCX1GX2X3X4GX5AGX6X7X8X9X 10 CGTX 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 GX 24 X 25 X26X 27 X 28 AX 29 X 30 GX 31 X 32 X 33 X 34 X 35 X 36 AGACTGCTCGAGCTG-3'. The aptamer obtained by the application has the characteristics of simple operation, high sensitivity, low manufacturing cost and strong specificity, and has a broad application prospect in the detection of Fusobacterium nucleatum.

The present invention relates to a single-stranded DNA aptamer that binds to glutathione to inhibit oxidation of the glutathione or stabilize the glutathione, characterized in that the single-stranded DNA aptamer has one or more stem-loop structures; a method for oxidation prevention and stabilization of glutathione using the aptamer; and application to various fields such as pharmaceuticals, cosmetics, and food, using the aptamer. The aptamer of the present invention can be applied to various fields, such as pharmaceuticals, cosmetics, and food, which require oxidation prevention and stabilization of glutathione.

The invention discloses a chimeric antigen receptor targeting EGFRvIII and application of the chimeric antigen receptor. The chimeric antigen receptor sequentially comprises an EGFRvIII targeting nucleic acid aptamer, a transmembrane domain and an intracellular signal domain from an N end to a C end, the EGFRvIII targeted nucleic acid aptamer is an EGFRvIII specific DNA aptamer obtained on the basis of SELEX (systematic evolution of ligands by exponential enrichment) screening, can only be combined with an extracellular domain of the EGFRvIII, and is not combined with an EGFR (epidermal growth factor receptor) wild type; the intracellular signal domain comprises a costimulatory signal domain and an activation signal domain, the C end of the costimulatory signal domain is connected with the N end of the activation signal domain, and the EGFRvIII specific nucleic acid aptamer screened based on SELEX is adopted as a targeting domain, can only be specifically combined with the extracellular domain of EGFRvIII positive tumor cells, and is not subjected to cross combination with EGFR wild cells and normal cells, so that the EGFRvIII specific nucleic acid aptamer can be used for detecting EGFRvIII positive tumor cells, and the EGFRvIII specific nucleic acid aptamer can be used for detecting EGFRvIII positive tumor cells. The problem of off-target killing caused by the fact that a common antibody scFv fragment of a traditional chimeric antigen receptor (CAR) is easily combined with a wild type EGFR is fundamentally avoided.

The application belongs to the technical field of electrochemiluminescence detection, and discloses a preparation method of a thiamethoxam electrochemiluminescence sensor based on Fe / Zn-MOF@C-dots sensitization, which comprises the following steps: C-dots preparation, Fe / Zn-MOF preparation, Fe / Zn-MOF@C-dots preparation, modification of Fe / Zn-MOF@C-dots to the surface of a glassy carbon electrode through chitosan, then combination of a single strand of thiamethoxam DNA aptamer to the surface of the composite nanomaterial as a recognition element through a crosslinking agent, construction of a biosensor capable of recognizing thiamethoxam, electrochemical method detection and electrochemiluminescence method detection. The Fe / Zn-MOF@C-dots composite material is used as an electrochemiluminescence reagent for the first time, and compared with C-dots, the electrochemiluminescence signal of the Fe / Zn-MOF@C-dots is significantly enhanced; at the same time, the sensor uses DNA aptamer as a specific recognition element of the target molecule thiamethoxam, and effectively improves the selection performance of the sensor. The sensor shows significant repeatability, good selectivity and long-term stability, and can be used as an effective means for detecting thiamethoxam residues in agricultural products and origin environments.

The application provides a SETDB1 aptamer, a PROTAC constructed based on the aptamer and application, and relates to the technical field of biological medicines.The nucleotide sequence of the SETDB1 aptamer is any one of SEQ ID NO.1 or SEQ ID NO.2.Through SELEX screening, a DNA aptamer targeting SETDB1 is identified, and the DNA aptamer is specifically combined with a Tudor domain; based on the screened SETDB1 aptamer, a first PROTAC of SETDB1 is constructed.Single-chain PROTAC and double-chain PROTAC are synthesized, and the above-mentioned PROTACs are all targeted to degrade SETDB1 in tumors, and have no effect on non-tumor cells or tissues.

The invention belongs to the field of aquatic bacteria detection, and relates to a fluorescent array sensor as well as a preparation method and application thereof. The fluorescent array sensor comprises a plurality of DNA aptamers, the DNA aptamers respectively target lipopolysaccharide, peptidoglycan and flagellin, the DNA aptamers of the target lipopolysaccharide are EA5 and LA27, the DNA aptamer of the target peptidoglycan is Antibac2, and the DNA aptamer of the target flagellin is Aptamer 3; the sequence of the EA5 is shown as SEQ ID NO.1, the sequence of the LA27 is shown as SEQ ID NO.2, the sequence of the Antibac2 is shown as SEQ ID NO.3, and the sequence of the Aptamer 3 is shown as SEQ ID NO.4. The invention further discloses a kit for detecting the content of the EA5, the LA27, the Antibac2 and the Aptamer. According to the present invention, the six bacteria can be simultaneously detected, the detection limit is low, the operation process is simple, and the detection accuracy can achieve 97.6%.

The present invention relates to a DNA aptamer specifically binding to an alpha-synuclein protein and uses thereof. Specifically, the present invention relates to a DNA aptamer selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1 to 12 and binding specifically to an α-synuclein protein, and a composition for detecting an α-synuclein protein, a detection kit, a detection chip or a microarray, all comprising the aptamer as an active ingredient. In addition, the present invention relates to a method for detecting an α-synuclein protein, a method for providing information for diagnosing a degenerative brain disease, a composition for diagnosing a degenerative brain disease, and a pharmaceutical composition for preventing or treating a neurodegenerative disease, all using the DNA aptamer of the present invention.

The application discloses a one-step monoclonal antibody drug electrochemical detection biosensor and a preparation method and application thereof. The application designs and screens an affinity specific DNA aptamer hairpin probe and uses the same as a specific capture unit, then uses a gold-sulfur bond to fix the DNA aptamer hairpin probe on a screen-printed electrode surface, meanwhile, uses a self-assembly interaction between a metal and a mercapto group to fix a blocking agent introduced on the screen-printed electrode surface, and blocks the excess electrode surface reaction sites, so that the one-step monoclonal antibody drug electrochemical detection biosensor is obtained. The one-step monoclonal antibody drug electrochemical detection biosensor has the advantages of simple operation, high sensitivity, less non-specific adsorption, high capture efficiency, stable physical and chemical properties, strong specificity and good selectivity, and can be used for capturing antibody drugs in complex biological samples.

The present disclosure relates to aptamers that specifically bind to Cytokeratin 8 (CK8) and / or Cytokeratin 18 (CK18) and their use as biomarkers for the detection of cancer, preferably carcinoma or adenocarcinoma. The present disclosure also relates to an intraoperative surgical pathology method that provides for the rapid identification of cancer cells, in particular carcinoma or adenocarcinoma, in a biological sample.

The application relates to the technical field of nanomaterials, in particular to an EpCAM aptamer modified nanomaterial and a preparation method and application thereof, wherein the nanomaterial takes carboxylated mesoporous silica nanoparticles as a carrier, and an EpCAM specific DNA aptamer is covalently coupled to the surface of the nanomaterial; the sequence of the EpCAM specific DNA aptamer is shown as SEQ ID No. 1. The nanomaterial can specifically capture tumor-derived exosomes (EVs) in blood, and can realize sensitive detection of EVs in the 7-day (early stage) and 21-day (late stage) stages of an HT29 colon cancer model and the 7-day stage of an A549 / H460 lung cancer model, thereby providing a minimally invasive liquid biopsy new tool for early diagnosis of colon cancer and lung cancer, and solving the inherent limitation problems of sensitivity and specificity of existing diagnosis means in cancer detection.

The present invention provides immunostimulatory nucleic acids that have an affinity to a specific target protein. The present invention also provides templates and methods for making and using the immunostimulatory nucleic acids. Further, methods for linking the immunostimulatory nucleic acids to antigens and using the resulting complexes to enhance an immune response are provided.

The invention relates to a positively charged peptide capable of non-covalently interact with negatively charged extracellular vesicles or nanoparticles. Said peptide is a fragment of the bacterial protein P40 and shows better interaction capabilities that the entire bacterial protein P40. The peptide of the invention can also be linked to a targeting element, such as targeting peptide, DNA aptamer, RNA aptamer, a protein, an antibody or a fragment thereof that binds to a target molecule, therefore it can be used for the targeted delivery of extracellular vesicles or nanoparticles further comprising a bioactive agent to a target cell, tissue or particle like a virus, that comprise the target molecule. Therefore, the present invention also relates to a carrier complex comprising the peptide of the invention non covalently bound to an extracellular vesicle or nanoparticle comprising a bioactive agent and its uses.

The application discloses a DNA aptamer binding to LOX-1 protein and application thereof. Specifically, the application provides a DNA aptamer binding to LOX-1 protein, wherein a core sequence of the DNA aptamer binding to the LOX-1 protein comprises a sequence as shown in SEQ ID NO: 5. The aptamer has small molecular weight, stable chemical property, is easy to preserve and label, can be combined with the LOX-1 protein through space conformation matching, accumulation of bases in a sequence, electrostatic interaction between charged groups or hydrogen bond interaction, and the like, has high affinity and good specificity.

The invention relates to the technical field of analytical chemistry, and particularly discloses a double-signal reverse change ratio type up-conversion nanoprobe for lead ion detection as well as a preparation method and application of the double-signal reverse change ratio type up-conversion nanoprobe. The double-signal reverse change ratio type up-conversion nanoprobe for lead ion detection comprises an up-conversion nanoparticle coated with polyacrylic acid and a DNA (Deoxyribose Nucleic Acid) aptamer modified by Cy3, wherein the Cy3 modified DNA aptamer is used as a specific recognition unit of Pb < 2 + >, the Cy3 is used as an energy receptor, and the polyacrylic acid coated up-conversion nanoparticles are used as an energy donor. According to the double-signal reverse change ratio type up-conversion nanoprobe, the DNA aptamer is induced to generate conformational change through specific binding of the DNA aptamer and Pb < 2 + >, the distance between up-conversion nanoparticles and Cy3 is shortened, and a ratio type detection signal is constructed through quenching of an emission peak of the up-conversion nanoparticles at 540 nm and enhancement of an emission peak of Cy3 at 565 nm; finally, high-sensitivity and high-selectivity detection on trace Pb < 2 + > is realized, and the detection sensitivity is improved.

The present disclosure relates to novel DNA aptamers and use thereof. In particular, the present disclosure relates to DNA aptamers selected from a DNA library using Cell-SELEX to bind specifically to cancer cells. The DNA aptamers of the present disclosure selected and optimized for high binding affinity to cancer cells can be effectively used for the diagnosis of cancer as they have enhanced targeting efficiencies for target cells and tissues.

The application belongs to the field of biomedical detection, and relates to a multi-modal nano probe NETs detection kit, a preparation method thereof and a NETs concentration detection method. The multi-modal nano probe NETs detection kit comprises a nano probe and a chemiluminescence working solution. The nano probe comprises a gold nano star, a histone H3 antibody-glucose oxidase conjugate fixed on the surface of the gold nano star, an MPO antibody-horseradish peroxidase conjugate and a double-stranded DNA aptamer-alkaline phosphatase conjugate. The chemiluminescence working solution is a Tris-HCl buffer solution containing glucose, luminol, p-nitrophenyl phosphate and an enhancer. In the application, after the nano probe is combined with NETs, the addition of the chemiluminescence working solution can form an efficient signal amplification network, the detection sensitivity of the kit to NETs can reach 0.02 nM, and low-concentration NETs of early inflammatory patients can be accurately detected.

The invention discloses a DNA (Deoxyribose Nucleic Acid) aptamer for targeting nucleolin and application of the DNA aptamer, belongs to the technical field of oligonucleotides, and particularly relates to the DNA aptamer for targeting nucleolin. The DNA nucleic acid aptamer is obtained by reacting AS1411 of which the 5'end is modified by amino and a triptolide derivative; the triptolide derivative is obtained by modifying triptolide with a vinyl carboxylic acid derivative; the vinyl carboxylic acid derivative is prepared by the following preparation steps: under the action of a catalyst, allyl succinic anhydride firstly reacts with 4-(chloromethyl) benzyl alcohol, and then reacts with sodium bicarbonate to obtain the vinyl carboxylic acid derivative. The DNA aptamer for targeting nucleolin disclosed by the invention not only can be efficiently combined with nucleolin, but also has good effects of inhibiting tumor cell proliferation and inhibiting tumor growth.

The application discloses a non-natural base DNA aptamer targeting Bacillus cereus 5 / B / 6 metal beta-lactamase and a screening method thereof. The screening method uses dNaMTP and dTPT3TP, or dCNMOTP and dTPT3TP as non-natural base nucleoside triphosphate substrates, uses OneTaq DNA polymerase to amplify a DNA library containing non-natural bases, and uses lamda exonuclease to degrade 5' end phosphorylated DNA chains in PCR products, so as to obtain two ssDNA libraries. The non-natural base DNA aptamer targeting Bacillus cereus 5 / B / 6 metal beta-lactamase is screened based on the libraries, and three non-natural base DNA aptamers with a length of 70 nt are obtained. The results of a biological membrane layer interference analysis show that the three non-natural base DNA aptamers have good binding affinity to Bacillus cereus 5 / B / 6 metal beta-lactamase.

The invention relates to the technical field of biological medicine and food safety, and discloses a preparation method of an aflatoxin B1 adsorbent, which comprises the following steps: co-incubating animal cell suspension treated by benzenesulfonyl fluoride, a photoinitiator and a gel monomer, collecting cell particles by low-speed centrifugation, and removing redundant photoinitiator and gel monomer to obtain an aflatoxin B1 adsorbent; irradiating by a 365 nm ultraviolet lamp to prepare gelatinized cell particles; and co-incubating the prepared gelated cell suspension and a cationic polymer solution, carrying out low-speed centrifugation to remove redundant polymer, and co-incubating the DNA aptamer and the treated gelated cells to finally obtain the DNA aptamer-loaded gelated cell particles (DNA-GC). The DNA-GC adsorbent prepared by the invention shows extremely high affinity and selectivity to aflatoxin B1 (AFB1), and can be used for accurately identifying and capturing AFB1 molecules in a complex biological medium.

The invention discloses a DNA aptamer for recognizing microbial transglutaminase and a screening method of the DNA aptamer, and belongs to the technical field of molecular biological detection. According to the invention, the high-affinity and high-specificity DNA aptamer aiming at microbial transglutaminase (MTGase) is obtained through screening for the first time, and the blank of the target in the aptamer recognition field is filled. The reverse screening step is introduced in the screening process, so that non-specific binding sequences with coexisting proteins are effectively removed, and the selectivity of the aptamer is remarkably improved. By combining multiple means such as FP, ITC, CD and molecular docking, the binding capacity and mechanism of the aptamer are systematically verified, and the reliability and scientificity of a screening result are ensured. The obtained aptamer has excellent affinity with MTGase, the dissociation constant can reach the nanomole level, and a molecular basis is provided for subsequent development of related recognition and detection technologies.

This invention provides a CRISPR-Cas12a-based nanopore sensor and its application in IGF-1 protein detection, belonging to the fields of biosensing and molecular diagnostics. The nanopore sensor includes: a solid-state nanopore unit, which is a glass capillary nanoparticle with an opening at the tip and a conductive layer covering the inner wall of the nanoparticle; a reporter molecule chemically bonded to the conductive layer; a protein recognition and signal conversion unit, including a DNA aptamer capable of specifically binding to Atlantic salmon IGF-1 protein and a single-stranded DNA complementary strand partially complementary to the DNA aptamer; and a signal amplification unit containing the Cas12a protein and crRNA complementary to the target DNA strand. This sensor achieves efficient, sensitive, and specific conversion from protein to electrical signal through a cleverly designed molecular competition system.

The invention belongs to the field of biomedical detection, and relates to a multi-mode nanoprobe NETs detection kit, a preparation method thereof and a detection method of NETs concentration. The multi-mode nanoprobe NETs detection kit comprises a nanoprobe and a chemiluminescence working solution, wherein the nanoprobe comprises a gold nanostar, and a histone H3 antibody-glucose oxidase conjugate, an MPO antibody-horseradish peroxidase conjugate and a double-chain DNA aptamer-alkaline phosphatase conjugate which are fixed on the surface of the gold nanostar. The chemiluminescence working solution is a Tris-HCl buffer solution containing glucose, luminol, p-nitrophenyl phosphate and a reinforcing agent. According to the kit, after the nanoprobe is combined with the NETs, an efficient signal amplification network can be formed by adding the chemiluminescence working solution, the detection sensitivity of the kit to the NETs can reach 0.02 nM, and the low-concentration NETs of early-stage inflammation patients can be accurately detected.

The invention relates to a DNA (deoxyribonucleic acid) aptamer which is shown as a formula I and can be specifically combined with abrus precatorius toxin and exert inhibitory activity and application of the DNA aptamer in prevention or treatment of abrus precatorius toxin poisoning. The nucleic acid aptamer can be combined with the abrus precatorius toxin in a high-affinity and high-specificity mode, and the toxicity of the abrus precatorius toxin is effectively resisted. The invention also designs a pharmaceutical composition containing the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof as an active ingredient, and an application of the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof in preparation of an abrus precatorius toxin antidote drug. In addition, the nucleic acid aptamer can also be used for resisting the abrus precatorius toxin in vitro or used as a detection tool for detecting the abrus precatorius toxin in environmental and biological samples. The invention provides a new solution for first aid, treatment and detection of the abrus precatorius toxin.

The application discloses a CEA detection kit, a detection method and application, and belongs to the technical field of biological medicines. The technical problems to be solved are to provide a CEA detection kit to solve the technical problems of dependence on complex equipment, cumbersome operation, insufficient specificity and sensitivity, and non-ideal signal output mode in the prior art. The technical solution points are a CEA detection kit, which comprises: a specific DNA aptamer of CEA; a biotin-labeled forward primer which is complementary to the specific DNA aptamer; a reverse primer which is used for amplifying a DNA template together with the forward primer; the DNA template comprises a sequence complementary to the forward primer and a sequence complementary to the reverse primer; and a CRISPR / Cas protein / crRNA complex, wherein the crRNA is complementary to the sequence of the amplification product of the DNA template.

Abstract A method for detecting a biological marker in a sample, preferably a biological marker on a cancer cell, the method comprising: (i) contacting the sample with at least one DNA aptamer coupled to a first reagent and wherein the aptamer specifically binds to a first biological marker in the sample to form a first complex; (ii) contacting the first complex of (i) with a second binding agent that specifically binds to the first reagent such that a second complex is formed, wherein the second binding agent is coupled to a reporter molecule; (iii) contacting the second complex (ii) with a substrate for the reporter molecule of the at least one second binding agent; and (iv) detecting the substrate reaction by formation of a reaction product thereby detecting the biological marker in the sample. Biological markers include cytokeratin 8 (CK8), cytokeratin 18 (CK18), human epidermal growth factor receptor 2 (HER2) and epithelial cell adhesion molecule (EpCAM). Abstract 41 / 50 FIGURE 40 Frozen section preparation 4 Sample fixation + Wash (10 dips in PBS) DNA aptamer staining DAB Substrate DAB substrate HRP FAM Anti-FITC conjugated with HRP FAM DNA Aptamer conjugated with FAM HRP Frozen section slide / Touch imprint slide / Cytology slide / Direct smear slide Anti-FITC-HRP Wash (10 dips in PBS) DAB Wash (10 dips in PBS) Hematoxylin counter-staining Wash under tap water Cove rs lip DAB brown precipitate at the location of the aptamer B o min 1 min 15 sec 5 min 15 sec 5 min 15 sec 5 min 15 sec 10 sec 1 min 1 min A + Wash (10 dips in PBS) Total time for aptamer-DAB staining: —18 min 4 1 / 5 0 A B 1 0 m i n 1 m i n D A B s u b s t r a t e 1 5 s e c H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n 1 5 s e c D N A A p t a m e r c o n j u g a t e d w i t h F A M 5 m i n D A B W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 020 25 28 36 33 19 D ec 2 02 5 1 9 D e c 2 0 2 5 A B 1 0 m i n F r o z e n s e c t i o n p r e p a r a t i o n 1 m i n S a m p l e f i x a t i o n D A B 2 0 2 5 2 8 3 6 3 3 s u b s t r a t e 1 5 s e c W a s h ( 1 0 d i p s i n P B S ) H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n A n t i - F I T C - H R P T o t a l t i m e f o r 1 5 s e c D N A A p t a m e r W a s h ( 1 0 d i p s i n P B S ) c o n j u g a t e d w i t h F A M 5 m i n D A B s t a i n i n g : ~ 1 8 m i n W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / 1 0 s e c H e m a t o x y l i n C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 0

This invention discloses a highly sensitive LCN2 detection kit and its preparation method for assessing the prognostic risk of patients with stress-induced cardiomyopathy. The kit contains a signal probe composed of rare-earth-doped upconversion nanoparticles and an LCN2-specific DNA aptamer, as well as a complementary oligonucleotide quenching probe with a quenching group. Its core principle is based on fluorescence resonance energy transfer regulated by competitive binding: when the target protein LCN2 is absent, the binding of the two probes leads to luminescence quenching; when LCN2 is present, they competitively bind to the aptamer and dissociate the quenching probe, thereby restoring upconversion luminescence. This homogeneous detection method effectively avoids the interference of autofluorescence in biological samples by utilizing near-infrared excitation. Combined with the high stability and specificity of the aptamer, it achieves a simple, rapid, highly specific, and ultra-sensitive quantitative detection of LCN2 protein in serum, providing a reliable tool for clinical prognostic assessment.

The invention discloses a self-driven functionalized nucleic acid assembly inspired by a blood coagulation mechanism and a preparation method of the self-driven functionalized nucleic acid assembly, and belongs to the technical field of medical blood coagulation materials. The functionalized nucleic acid assembly is formed by rolling circle amplification of four blood coagulation related functionalized DNA (deoxyribonucleic acid) aptamers as shown in SEQ ID NO: 1-4. In addition, the functionalized nucleic acid assembly is loaded with the spearhead agkistrodon halys hemocoagulase, so that an exogenous material can be enhanced to trigger an organism to activate a blood coagulation cascade reaction. The Chinese herbal medicine hirudin is loaded in the functionalized nucleic acid assembly, so that thrombus formation and circulatory system diseases can be effectively prevented. The functional nucleic acid assembly blood coagulation material is reasonable in structural design and mature and feasible in manufacturing process, can be widely applied to treatment of complex wounds such as hidden deep-invasive hemorrhagic spots and circulatory system diseases, can also be further added into products such as medical dressings, hemostatic gel and hemostatic spray, and has a good application prospect.

This disclosure relates to DNA aptamers that bind eosinophil peroxidase, including uses thereof, such as in eosinophil peroxidase detection assays. Also provided is a method for detecting the presence of eosinophil peroxidase in a sample, using the DNA aptamers that bind eosinophil peroxidase. Further provided is a kit for detecting the presence of eosinophil peroxidase in a sample, using the DNA aptamers that bind eosinophil peroxidase.